Utility of biochemical markers of bone turnover in diagnosis of osteoporosis and fracture risk prediction

##plugins.themes.academic_pro.article.sidebar##

Published Sep 12, 2014
Download
pdf
Vol. 92 No. 5 (2014): Issue May 2014

##plugins.themes.academic_pro.article.main##

M. Younes
H. Hachfi
F. Hassine Neffati
S. Zrour
B. Ismail
M. Touzi
M. F.Najjar
N. Bergaoui

Abstract

Background: Currently, for the diagnosis of osteoporosis, we search risk factors and measure bone mineral density (BMD) by DXA

method. However, bone turnover markers, unused still in practice, have shown an interest especially in the prediction of fracture risk. aim: To determine the relationship between bone markers, BMD and osteoporotic fracture.

methods: Prospective study of 65 women referred for measure of BMD during the period between May and August 2010. Each patient had a dosage of serum bone formation markers: osteocalcin (OC) and N-terminal propeptide of type I collagen (P1NP) and bone resorption markers: serum and urinary C-terminal telopeptide of type I collagen (β-CTX or CrossLaps) as well as parathyroid hormone and calcium. Risk factors of osteoporosis were identified in each case. results: Our 65 women had a mean age of 58.6 ± 12.1 years. The majority (83%) were menopausal women. Osteoporosis was found in 52%, osteopenia 26% and normal BMD 22% of cases. An increase in bone turnover markers was correlated with menopause (p = 0. 001 for the OC, p = 0.016 for urinary CTX), a low body mass index (p = 0.015 for OC, p = 0.042 for serum CTX) and osteoporosis (p <0.001 for P1NP, p <0.001 for serum and urinary CTX). Corticosteroid therapy was correlated with a decrease in bone formation markers (p = 0.002 for P1NP). The presence of fracture was only associated with increased urinary CTX (p = 0.05).

Conclusion: Bone turnover markers increase in menopausal women and in case of low BMD. However, their contribution in the diagnosis of osteoporosis is low. They are rather an interest in the prediction of fracture risk.

Keywords:

Osteoporosis, bone turnover markers, risk factors, fracture.

##plugins.themes.academic_pro.article.details##

References

  1. Meunier PJ. Les défis épidémiologiques et thérapeuthiques de l'ostéoporose. Rev Rhum 2005 ; 72 : S1-S3.
  2. Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep. 2009; 7:84-90.
  3. Brown Jp, Albert C, Nassar Ba Et Al. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem. 2009; 42:929-42.
  4. Lukaszkiewicz J, Karczmarewicz E, PÅ‚udowski P Et AL. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study. Med Sci Monit. 2008; 14: 65-70.
  5. Singer Fr, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med. 2008; 75:739-50.
  6. Camacho Pm, Lopez NA. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med. 2008; 46:1345-57.
  7. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008; 12:157-70.
  8. Briot K, Roux C. Les marqueurs biochimiques du remodelage osseux. Gynecol Obstet Fertil 2005; 33: 1009-13.
  9. Hellara I, Mezzour H, Younes M, Neffati F, Bergaoui N, Najjar MF. L'ostéoporose : étude rétrospective de 47 cas. Rev Tun Biol Clin 2006 ; 19 : 30-41
  10. Roux C, Meunier JP. Les Investigateurs DEIMOS. Enquête DEIMOS en rhumatologie : de la suspicion à la confirmation du diagnostic d'ostéoporose chez la femme ménopausée. Rev Rhum 2007 ; 74 :1110-11.
  11. Orcel P, Krane Sm. Ostéoporoses secondaires et ostéoporose cortisonique. Ann Med Interne 2000 ; 151: 497-503.
  12. Hammoumraoui N, El Rakawi M, Lehtihet S, Djoudi H. La grande multiparié et l'allaitement prolongé sont-ils des facteurs de risque ou des facteurs protecteurs de l'ostéoporose? Rev Rhum 2006, 73 : 1146.
  13. Goemaere S, Van Pottelberg I, Zmierczak H, Toye K, Daems M, Demuynch R. Inverse Association Between Bone Turnover Rate and Bone Mineral Density in Community-dwelling Men>70years of Age : No Major Role of Sex Steroid Status. Bone 2001; 29:286-91.
  14. Chandani Ak, Scariano Jk, Glew Rh, Clemens Pj, Baumgartner RN. Bone Mineral Density and Serum Levels of Aminoterminal Propeptides and Cross-Linked N-telopeptides of Type I Collagen in Eldery Men. Bone 2000; 26: 513-18.
  15. Melton Iii Lj, Khosla S, Atkinson Ej, O'fallon Wm, Riggs Bl. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12:1083-91.
  16. Khosla S, Melton Ljiii, Atkinson Ej, O' Fallon Wm, Klee Gg, Riggs BL. Relationship Of Serum Sex Steroid Levels And Bone Turnover Markers With Bone Mineral Density In Men And Women. A Key Role For Bioavailbale Estrogen J. Clin Endocrionl Metab 1998:83: 2266-74.
  17. Khosla S, Atkinson Ej, Melton Ljiii, Riggs BL. Effects of Age and Estrogen Status on Serum Parathyroid Hormone Levels and Biochemical Markers of Bone Turnover in Women : A population -Based study. J. Clin Endocrionl Metab 1997:82: 1522-27.
  18. Achemlal L, Guerboub A, Mounach A Et Al. L'obésité est un facteur protecteur de l'ostéoporose chez les femmes âgées marocaines normales. Rev Rhum 2006; 73: 1154.
  19. Garnero P, Sornay-Rendu E, Chapuy Mc, Delmas PD. Increased bone turnover in late postmenopausal women is a major determination of osteoporosis. J.Bone Miner Res 1996; 11: 337- 49.
  20. Reginster Jy, Henrotin Y, Christiansen C Et Al. Bone Resorption In Post-Menopausal Women With Normal And Low BMD Assessed With Biochemical Markers Specific For Telopeptide Derived Degradation Products Od Collagen Type I. Calcif Tissue Int 2001, 69: 130-7.
  21. Minisola S, Del Fiacco R, Piemonte S Et Al. Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest.2008; 31(7 Suppl):28-32.
  22. Orcel P. Roux C. Ostéoporose cortisonique. Rev Rhum 2001; 68 : 678-84.
  23. Ravn P, Rix M, Andeassen H, Clemmesen B, Bidstrup M, Gunnes M. high bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcify Tissue Int 1997; 60: 255-60.
  24. Dominguez Cabrera C, Sosa Henriquez M, Traba Ml, Alvarez Villafane E, De La Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos Int 1998; 8: 147-51.
  25. Eastell R, Robins Sp, Colwell T, Assiri Am, Riggs Bl, Russel RG. Evaluation of bone turnover in type osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos Int 1993; 3: 255-60.
  26. Minisola S, Pacitti Mt, Ombricolo E Et Al. Bone Turover and its relationship with bone mineral density in pre-and postmenopausal women with or without fractures. Maturiats 1998; 29: 265-70.
  27. Hari Kumar Kv, Muthukrishnan J, Verma A, Modi KD. Correlation between bone markers and bone mineral density in postmenopausal women with osteoporosis. Endocr Pract 2008; 14: 1102-7.
  28. Szulc P, Arlot M, Chapuy Mc, Duboeuf F, Meunier Pj, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner res 1994; 9: 1591-5.
  29. Garnero P, Hausherr E, Chapuy Mc Et Al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-8.
  30. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526-36.
  31. Garnero P, Dargent-Molina P, Hans D Et Al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998; 8:563-9.
  32. Vasikaran S, Eastell R, Bruyère O ET AL. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391-420.
  33. Mccloskey Ev, Vasikaran S, Cooper C. Frax(®) Position Development Conference Members. Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J Clin Densitom 2011; 14:220-2.
  34. Paccou J. Evaluation du risque fracturaire au cours de l'ostéoporose post-ménopausique en pratique clinique à l'aide du FRAX® : place des marqueurs du remodelage osseux. Revue Francophone des Laboratoires 2012; 2012:53-6.